These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21195023)

  • 21. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C.
    Manolakopoulos S; Deutsch MJ; Anagnostou O; Karatapanis S; Tiniakou E; Papatheodoridis GV; Georgiou E; Manesis E; Tzourmakliotis D; Archimandritis AJ
    Liver Int; 2010 Nov; 30(10):1454-60. PubMed ID: 20846344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chronic hepatitis C. A new chance with Consensus Interferon for patients with handicaps].
    MMW Fortschr Med; 2002 Nov; 144(45):56-7. PubMed ID: 12534066
    [No Abstract]   [Full Text] [Related]  

  • 24. [Hepatitis C and liver transplantation].
    Durand F
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B82-90. PubMed ID: 12180312
    [No Abstract]   [Full Text] [Related]  

  • 25. [Quantification of hepatitis C virus RNA in serum].
    Kawai S; Yokosuka O
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):426-9. PubMed ID: 15359836
    [No Abstract]   [Full Text] [Related]  

  • 26. [ROC curve analysis of factors predictive of response to treatment with interferon plus ribavirin in patients with chronic hepatitis C relapse after previous interferon treatment].
    Olaso V; Córdoba J; Molina JM; López B; Siles MS; Monte E; Calvo F; Bau I; Beltrán B; Martínez B; Gobernado M
    Rev Esp Quimioter; 2002 Dec; 15(4):366-73. PubMed ID: 12587043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hepatitis C is curable. Even slightly elevated liver enzymes need further examination].
    Niederau C
    MMW Fortschr Med; 2008 Mar; 150(13):26. PubMed ID: 18522352
    [No Abstract]   [Full Text] [Related]  

  • 28. [Chronic hepatitis C and B. What can be accomplished with antiviral therapy].
    MMW Fortschr Med; 2007 Feb; 149(7):14. PubMed ID: 17615650
    [No Abstract]   [Full Text] [Related]  

  • 29. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study.
    Cornberg M; Hadem J; Herrmann E; Schuppert F; Schmidt HH; Reiser M; Marschal O; Steffen M; Manns MP; Wedemeyer H
    J Hepatol; 2006 Feb; 44(2):291-301. PubMed ID: 16360972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ribavirin in chronic hepatitis C: past and future.
    Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
    [No Abstract]   [Full Text] [Related]  

  • 32. [Antigen and viral load].
    Lunel F; Veillon P
    Transfus Clin Biol; 2003 Apr; 10(2):74-7. PubMed ID: 12763148
    [No Abstract]   [Full Text] [Related]  

  • 33. First-line treatments for hepatitis C.
    Messori A; Del Santo F; Maratea D
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1383-5. PubMed ID: 21569068
    [No Abstract]   [Full Text] [Related]  

  • 34. Has genetics eradicated the good old predictors of hepatitis C treatment response?
    Pawlotsky JM
    Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):157-8. PubMed ID: 21492738
    [No Abstract]   [Full Text] [Related]  

  • 35. A novel FRET probe-based approach for identification, quantification, and characterization of occult HCV infections in patients with cryptogenic liver cirrhosis.
    Bhargava A; Punde R; Varshney S; Pathak N; Mishra PK
    Indian J Pathol Microbiol; 2011; 54(2):420-1. PubMed ID: 21623119
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatitis C virus treatment revolution: need for close monitoring.
    Ippolito G; Antonelli G; Capobianchi MR; Lanini S
    Clin Microbiol Infect; 2014 Nov; 20(11):O790-1. PubMed ID: 24889740
    [No Abstract]   [Full Text] [Related]  

  • 37. Simplified diagnostic monitoring for hepatitis C, in the new era of direct-acting antiviral treatment.
    Cohn J; Roberts T; Amorosa V; Lemoine M; Hill A
    Curr Opin HIV AIDS; 2015 Sep; 10(5):369-73. PubMed ID: 26185920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased levels of serum amyloid A during the early phase of hepatitis C treatment with interferon are associated with sustained virologic response - a pilot study.
    Gschwantler M; Dulic M; Dulic-Lakovic E; Schwarzer R; Rieder F; Graninger W; Steininger C
    J Gastrointestin Liver Dis; 2014 Mar; 23(1):101-2. PubMed ID: 24689108
    [No Abstract]   [Full Text] [Related]  

  • 39. Assessment of the patient who failed treatment for chronic hepatitis C.
    Levine CD; Ghalib RH
    Gastroenterol Nurs; 2005; 28(3 Suppl):S24-30. PubMed ID: 15976557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Letter: new treatments for hepatitis C have implications for quality of life in people who inject drug--authors' reply.
    Stepanova M; Younossi Z
    Aliment Pharmacol Ther; 2016 Apr; 43(7):841-2. PubMed ID: 26932413
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.